Browse Results

  • Division: : Cancer Center
  • Therapeutic Area: Leukemia, Lymphoma, and Myeloma


There are 35 clinical trial(s) matching your criteria.

Back

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

Investigator: Lazaros Lekakis

Institutional Protocol #: 20160645

National Clinical Trials Identifier: NCT02701634

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 2/3/2017

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).

Investigator: James Hoffman

Institutional Protocol #: 20160548

National Clinical Trials Identifier: NCT01863550

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 12/19/2016

1138131 A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post- Polycythemic Myelofibrosis)

Investigator: Ronan Swords

Institutional Protocol #: 20151074

National Clinical Trials Identifier: NCT02530619

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I

Enrolling Since: 6/24/2016

Back